![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis' Afinitor Not Cost Effective, Says NICE
Novartis' Afinitor Not Cost Effective, Says NICE
September 2, 2013
Cost regulators for the NHS in England and Wales have confirmed that patients with advanced breast cancer will not be able to routinely access Novartis' Afinitor.
Pharma Times
Pharma Times
Upcoming Events
-
21Oct